Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK

J Urol. 2025 Jan;213(1):110-113. doi: 10.1097/JU.0000000000004228. Epub 2024 Sep 3.

Authors

Neal D Shore¹, Ugo De Giorgi², Stephen J Freedland^{3

4}

Affiliations

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
³ Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ The Durham VA Medical Center, Durham, North Carolina.

No abstract available

Keywords: EMBARK; enzalutamide; high-risk biochemical recurrence; prostate cancer.

Publication types

Editorial